{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:14:34Z","timestamp":1762607674577,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special","doi-asserted-by":"publisher","award":["2018-1-2181"],"award-info":[{"award-number":["2018-1-2181"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013385","name":"National Science and Technology Program during the Twelfth Five-year Plan Period","doi-asserted-by":"publisher","award":["2014ZX10002002-001-002"],"award-info":[{"award-number":["2014ZX10002002-001-002"]}],"id":[{"id":"10.13039\/501100013385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.meegid.2019.104101","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T04:38:30Z","timestamp":1572755910000},"page":"104101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The combination therapy of Peginterferon\u03b1 and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-1938","authenticated-orcid":false,"given":"Fang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuli","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanpin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lele","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2019.104101_bb0005","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","article-title":"High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma","volume":"26","author":"Chan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.meegid.2019.104101_bb0020","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/jmv.24013","article-title":"Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B","volume":"86","author":"Chen","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2019.104101_bb0025","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.meegid.2019.104101_bb0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2019.104101_bb0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hep.29874","article-title":"Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance","volume":"68","author":"Fung","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2019.104101_bb0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.meegid.2019.104101_bb0060","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2019.104101_bb0065","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2019.104101_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067481","article-title":"Clinical relevance of minimal residual Viremia during long-term therapy with Nucleos(t)ide analogues in patients with chronic hepatitis B","volume":"8","author":"Maier","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.meegid.2019.104101_bb0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2012.653340","article-title":"Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901","volume":"11","author":"Manns","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.meegid.2019.104101_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.meegid.2019.104101_bb0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2019.104101_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.meegid.2019.104101_bb0095","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2019.104101_bb0100","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5009\/gnl16215","article-title":"Combination therapy for chronic hepatitis B: current updates and perspectives","volume":"11","author":"Su","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.meegid.2019.104101_bb0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2016.05.024","article-title":"Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: a randomized controlled study","volume":"65","author":"Sun","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2019.104101_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0115","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.meegid.2019.104101_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: is there still a role for interferon?","volume":"38","author":"Vigano","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.meegid.2019.104101_bb0125","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.meegid.2019.104101_bb0130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jvh.12341","article-title":"Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B","volume":"21","author":"Wong","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.meegid.2019.104101_bb0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2019.104101_bb0140","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/0091270006293304","article-title":"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects","volume":"46","author":"Yan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2019.104101_bb0145","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134819303272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134819303272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:41:17Z","timestamp":1761576077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134819303272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":28,"alternative-id":["S1567134819303272"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2019.104101","relation":{},"ISSN":["1567-1348"],"issn-type":[{"type":"print","value":"1567-1348"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The combination therapy of Peginterferon\u03b1 and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2019.104101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104101"}}